Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare

Vasopressin [11000-17-2]

Stampa

Cat# HY-B1811-25mg

Size : 25mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Description

Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors^[1]^[2]^[3].

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A7R5	IC₅₀	10 nM Compound: vasopressin, VS2	Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells	10.1016/S0960-894X(97)00050-4
CHO	EC₅₀	2 nM Compound: AVP	Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	[PMID: 21428295]
CHO	EC₅₀	8.3 nM Compound: AVP	Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	[PMID: 21428295]
CHO-K1	EC₅₀	15 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay	[PMID: 21688787]
CHO-K1	EC₅₀	22 nM Compound: AVP	Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
COS-1	EC₅₀	41 nM Compound: 2, AVP	Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay	[PMID: 21117646]
Flp-In-293	EC₅₀	4.3 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.0035 nM Compound: AVP	Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.004 nM Compound: AVP	Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.05 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.05 nM Compound: AVP	Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	0.07 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.1 nM Compound: AVP	Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.24 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.24 nM Compound: AVP	Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	4.3 nM Compound: AVP	Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]

In Vitro

AVP (0.01 nM-1 μM) induces Ca²⁺ increase in Chinese hamster ovary cells expressing rat or human V_1b receptors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vasopressin (0.03-0.3 μg/kg; i.p.) potentiates corticotropin release provoked by exogenous corticoliberin and increases corticotropin secretion subsequent to body water loss^[2].
Vasopressin (0.001-0.1 mg/kg; i.p.) potently increases adjacent lying, where rats meeting for the first time lie passively next to each other^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

1084.23

Formule

C₄₆H₆₅N₁₅O₁₂S₂

CAS No.

11000-17-2

Appearance

Solid

Color

White to off-white

Sequence

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6)

Sequence Shortening

CYFQNCPRG-NH2 (Disulfide bridge: Cys1-Cys6)

Structure Classification

Cyclopeptides

Initial Source

Endogenous metabolite

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (92.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (46.12 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9223 mL	4.6116 mL	9.2231 mL
5 mM	0.1845 mL	0.9223 mL	1.8446 mL
10 mM	0.0922 mL	0.4612 mL	0.9223 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 25 mg/mL (23.06 mM); Clear solution; Need ultrasonic and warming

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Pureté et documentation

Purity: 99.65%

Fiche technique (284 KB) SDS (393 KB)

COA (260 KB) RP-HPLC (227 KB) MS (219 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Baribeau DA, et, al. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015 Sep 24;9:335. [Content Brief]

[2]. Ramos L, et, al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology. 2013 Oct;38(11):2249-59. [Content Brief]

[3]. Gal CSL, et, al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30. [Content Brief]

Si può anche essere interessati nei seguenti prodotti:

Cat#

Descrizione

Cond.

Priced

NB-64-03119-50mg

L-368,899 hydrochloride [160312-62-9]

50mg

HY-108677-50mg

L-368,899 hydrochloride [160312-62-9]

50mg

HY-B1811-10mg

Vasopressin [11000-17-2]

10mg

Vasopressin [11000-17-2]

Cat# HY-B1811-25mg

Marca : MedChemExpress

Vasopressin Related Antibodies

Si può anche essere interessati nei seguenti prodotti: